GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A8461 L-GlutamineSummary: Non-essential amino acid -
A8514 RisperidoneSummary: SR-2A inhibitor -
A8516 Rizatriptan BenzoateSummary: 5-HT Receptor agonist -
A8521 SilodosinSummary: α1-adrenoceptor antagonist -
A8384 BlonanserinSummary: Atypical antipsychotic -
A8402 Conivaptan HClSummary: Vasopressin receptor antagonist -
A8421 Duloxetine HClSummary: 5-HT receptor inhibitor -
A8474 Mirabegron (YM178)Target: adrenoceptorSummary: Selective β3-adrenoceptor agonist -
A8548 Fingolimod (FTY720)7 CitationTarget: S1P receptorsSummary: S1P receptors agonist -
B3225 BAF312 (Siponimod)1 CitationTarget: S1P receptorsSummary: S1P agonist,potent and selective

